AFT Pharmaceuticals to raise $33.2 mln in IPO at $2.80 a share, list on NZX, ASX

Jonathan Underhill
Thu, 26 Nov 2015

Nov. 26 (BusinessDesk) - AFT Pharmaceuticals, the Auckland-based company whose products include Maxigesic pain medication and Maxiclear PE nasal decongestant, plans to list on the NZX and ASX next month after it has raised $33.2 million in an initial public offering. The company set the price of 11.9 million shares to be offered at $2.80 apiece, following an institutional bookbuild, valuing AFT at $269 million, according to a draft company statement. The IPO includes $30.2 million of new capital to fund growth at AFT, while the trustees of t...

Not convinced yet?

Subscribe to our Daily News Update free newsletter.

The Quiz FREE
QuiznessDesk, Tuesday, July 05, 2022
The Quizmaster | Tue, 05 Jul 2022

Don't forget to give our daily quiz a go. Good luck

Law & Regulation
Juice magnate Lepionka sues lawyers for 'negligent' advice
Greg Hurrell | Tue, 05 Jul 2022

Businessman Stefan Lepionka's negligence case against Gibson Sheat will be split in two, with the law firm's countersuit to be heard first, the high court has ruled.

Property
George Kerr's Pyne Gould receivership continues
Victoria Young | Tue, 05 Jul 2022

Court action continues in the UK, while receivers have already clawed back $8m for the BNZ by selling South Island land.

Sponsored
How can Kiwi small business owners manage rising inflation?

Xero MD Craig Hudson says small businesses have been hit with a triple whammy.

Sponsored
Digital innovation could shape the future of NZ

The digital age allows us to collaborate on some of our greatest scientific and environmental challenges